Key Takeaways Shares of WW International, better known as WeightWatchers, soared Tuesday after it said it is offering copycat weight-loss drugs to its members. The compounded treatments will contain the same active ingredient as Novo Nordisk's weight-loss medicines. Shares of the company have slumped as the boom in weight-loss drugs has cut into demand for WeightWatchers' services. Shares of WW International (WW), better known as WeightWatchers, jumped nearly 25% Tuesday when the dieting services company an ...

Group 1 - WeightWatchers CEO Sima Sistani has stepped down after 2½ years, with Tara Comonte appointed as interim CEO [1] - During Sistani's tenure, WeightWatchers acquired telehealth platform Sequence, now known as WeightWatchers Clinic, to expand into obesity drug prescriptions [2] - The company's shares have dropped approximately 90% this year, largely due to the rising popularity of GLP-1 drugs like Ozempic and Wegovy, which have affected its traditional weight loss program [2] Group 2 - The company reaffirmed its full-year 2024 forecast for revenue and adjusted operating income [4] - Comonte joined the WeightWatchers board in June 2023 and has prior experience as CEO of TMRW Life Sciences and as president and CFO of Shake Shack [3]

Independent Board Member Tara Comonte Will Serve as Interim Chief Executive Officer Sima Sistani Will Step Down as CEO and Director NEW YORK, Sept. 27, 2024 (GLOBE NEWSWIRE) -- WW International, Inc. (NASDAQ: WW) ("WeightWatchers," "WW," or the "Company") announced today that WeightWatchers Board member Tara Comonte has been appointed Interim Chief Executive Officer. Ms. Comonte succeeds Sima Sistani, who departs from her role as Chief Executive Officer and as a member of the Board, effective today. During ...

WW International (WW) came out with a quarterly loss of $0.13 per share versus the Zacks Consensus Estimate of $0.03. This compares to loss of $0.04 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of -533.33%. A quarter ago, it was expected that this weight-loss program operator would post a loss of $0.43 per share when it actually produced a loss of $0.06, delivering a surprise of 86.05%. Over the last four quarters, the compan ...

Core Insights - WW International, Inc. reported a total revenue of $202.1 million for Q2 2024, a decrease of 10.9% compared to the same period last year [2][4] - The company has announced a restructuring plan aimed at achieving $100 million in annual run-rate cost savings [1][6] - The end of period subscribers decreased by 6.1% year-over-year, with notable declines in Digital and Workshops + Digital segments [3][17] Financial Performance - Subscription revenues for Q2 2024 were $200.0 million, down 5.7% from $212.1 million in Q2 2023 [2][5] - Gross profit for Q2 2024 was $137.3 million, resulting in a gross margin of 67.9%, an increase from 63.1% in the prior year [4][5] - Operating income increased to $35.9 million, up 36.5% from $26.3 million in the prior year [2][5] Subscriber Metrics - Total end of period subscribers were 3.8 million, down from 4.1 million a year ago [2][3] - Digital subscribers decreased by 4.2% to 3.2 million, while Workshops + Digital subscribers fell by 21.4% to 0.6 million [3][17] - Clinical subscribers saw a significant increase of 119.8%, reaching 0.1 million [3][17] Cost Management and Restructuring - The company is implementing a 2024 Restructuring Plan, which includes a reduction in workforce and is expected to incur restructuring charges between $12 million to $15 million in the second half of fiscal 2024 [1][6] - The restructuring plan is part of a broader strategy to streamline operations and optimize the clinical and behavioral product portfolio [1][6] Guidance and Future Outlook - For the full year fiscal 2024, the company expects revenues to be at least $770.0 million and an operating loss of at most $180.7 million [7] - Adjusted operating income is projected to be at least $100.0 million, excluding non-cash intangible impairment charges and restructuring impacts [7]

NEW YORK, July 18, 2024 (GLOBE NEWSWIRE) -- WW International, Inc. (NASDAQ: WW) ("WeightWatchers," "WW," or "the Company") will release its results for the second quarter 2024 before market open on Thursday, August 1, 2024. WeightWatchers will host a conference call at 8:30 a.m. ET the same day. During the conference call, Sima Sistani, Chief Executive Officer, and Heather Stark, Chief Financial Officer, will discuss the second quarter 2024 results and answer questions from the investment community. The liv ...

WW International, Inc. (NASDAQ:WW) Q1 2024 Earnings Conference Call May 2, 2024 5:00 PM ET Company Participants Corey Kinger - IR Sima Sistani - CEO Heather Stark - CFO Conference Call Participants Jack Wallace - Guggenheim Nathan Feather - Morgan Stanley Linda Bolton - D.A. Davidson Alex Fuhrman - Craig-Hallum Capital Group Stephanie Davis - Barclays Karru Martinson - Jefferies Jack Wallace - Guggenheim Nathan Feather - Morgan Stanley Operator Good day and welcome to the Weight Watchers International's Fir ...

Subscriber Metrics - End of period subscribers reached 4.0 million, including 91 thousand clinical subscribers[4] - End of period total subscribers slightly decreased by 0.4% to 4,008 from 4,022 year-over-year[31] Financial Performance - Revenues for Q1 2024 were $206.5 million, a decrease of 14.6% compared to the prior year[10] - Total revenues for Q1 2024 were $206,548, down 14.6% from $241,895 in Q1 2023[25] - Subscription revenues were $204.1 million, down 3.3% year-over-year, including $18.8 million from clinical subscriptions[10] - Subscription revenues for Q1 2024 were $204,056, a decrease of 3.7% from $211,032 in Q1 2023[25] - Other revenues decreased by 91.9% to $2.5 million, primarily due to the wind down of the consumer products business[10] - Digital subscription revenues decreased by 7.8% to $137,633 from $149,344 year-over-year[35] Profitability and Losses - Operating loss for Q1 2024 was $269.3 million, primarily due to $258.0 million in non-cash intangible impairment charges[10] - The company reported an operating loss of $269,332 for Q1 2024, compared to an operating loss of $28,583 in Q1 2023[25] - Net loss for Q1 2024 was $347.9 million, compared to a net loss of $118.7 million in the prior year[12] - The net loss for Q1 2024 was $347,902, compared to a net loss of $118,679 in Q1 2023, representing a significant increase in losses[25] - Adjusted EBITDAS for Q1 2024 was $8,803, down from $11,068 in Q1 2023[47] Guidance and Projections - The company maintains revenue guidance for fiscal 2024 in the range of $830.0 million to $860.0 million[16] - Adjusted operating income is expected to be in the range of $100.0 million to $110.0 million, excluding impairment and restructuring charges[16] - The Company provided operating loss guidance for Full Year 2024 in the range of $(163.7) million to $(153.7) million[56] - Adjusted operating income is projected to be between $100.0 million and $110.0 million for Full Year 2024[56] Impairment Charges - The company recognized impairment charges of $257,988 related to franchise rights acquired in Q1 2024[25] - The Company reported impairment charges of $2,383 million and $1,203 million related to its Republic of Ireland and Northern Ireland reporting units, respectively[52] - Impairment charges for franchise rights acquired totaled $251,431 million, $4,074 million, $2,328 million, and $155 million for the United States, Australia, New Zealand, and United Kingdom units, respectively[52] - The impairment charges related to franchise rights acquired in the first quarter of fiscal 2024 are reflected in the overall impairment totals[57] Cash and Assets - Cash and cash equivalents decreased to $66,615 at the end of Q1 2024 from $109,366 at the end of Q4 2023, a decline of 39%[29] - Total assets decreased to $654,248 as of March 30, 2024, down from $982,030 as of December 30, 2023[23] - Total liabilities increased to $1,766,547 as of March 30, 2024, compared to $1,743,124 as of December 30, 2023[23] - Total debt as of Q1 2024 was $1,427,509, with net debt of $1,360,894 after accounting for cash[51] Operational Changes - The company is focused on expanding its community offerings and enhancing its existing services to meet evolving consumer preferences[20] - The Company is undergoing a restructuring plan disclosed for 2023, with associated charges impacting financial results[53] - Non-recurring transaction costs were incurred in connection with the Company's acquisition of Sequence[54] Paid Weeks - Total paid weeks increased by 1.7% year-over-year, driven by the digital business and clinical paid weeks[10] - Total paid weeks increased by 1.7% to 51,799 in Q1 2024 from 50,952 in Q1 2023[31] Share Metrics - The weighted average common shares outstanding for Q1 2024 were 79,208, an increase from 70,596 in Q1 2023[25]

WW International, Inc. (NASDAQ:WW) Q4 2023 Earnings Conference Call February 28, 2024 5:00 PM ET Company Participants Corey Kinger - Investor Relations Sima Sistani - Chief Executive Officer Heather Stark - Chief Financial Officer Conference Call Participants Nathan Feather - Morgan Stanley Jack Wallace - Guggenheim Michael Lasser - UBS Alex Fuhrman - Craig-Hallum Capital Group Stephanie Davis - Barclays Operator Hello and welcome to the WW International's Fourth Quarter and Full Year 2023 Earnings Conferen ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-16769 WW INTERNATIONAL, INC. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organizatio ...